# The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE

> **NCT07306585** · PHASE1 · NOT_YET_RECRUITING · sponsor: **HC Biopharma Inc.** · enrollment: 32 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)
- Cutaneous Lupus Erythematosus (CLE)

## Interventions

- **DRUG:** HC022
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07306585
- **Lead sponsor:** HC Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-30
- **Primary completion:** 2027-03-28
- **Final completion:** 2027-09-24
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07306585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07306585, "The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07306585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*